| Budget Amount *help |
¥197,340,000 (Direct Cost: ¥151,800,000、Indirect Cost: ¥45,540,000)
Fiscal Year 2014: ¥41,340,000 (Direct Cost: ¥31,800,000、Indirect Cost: ¥9,540,000)
Fiscal Year 2013: ¥43,290,000 (Direct Cost: ¥33,300,000、Indirect Cost: ¥9,990,000)
Fiscal Year 2012: ¥37,440,000 (Direct Cost: ¥28,800,000、Indirect Cost: ¥8,640,000)
Fiscal Year 2011: ¥37,050,000 (Direct Cost: ¥28,500,000、Indirect Cost: ¥8,550,000)
Fiscal Year 2010: ¥38,220,000 (Direct Cost: ¥29,400,000、Indirect Cost: ¥8,820,000)
|
|---|
| Outline of Final Research Achievements |
By in vivo imaging with two-photon microscopy and by live imaging with confocal microscopy, we revealed the pathological processes from molecular dysfunctions to synapse dysfunctions in Alzheimer’s disease, polyglot diseases, intellectual disability and microcephaly. Moreover, we showed the possibility of AAV-based gene therapies to restore molecular dysfunctions in the brain and to recover the symptoms of spinocerebellar ataxia, intellectual disability and microcephaly and to improve synapse level abnormality of Alzheimer’s disease in each mouse model.
|
